2 to 11 years:
Fluticasone furoate: 1 spray ( mcg/spray) in each nostril once a day
4 to 11 years:
Fluticasone propionate: 1 spray (50 mcg/spray) in each nostril once a day
12 years or older:
Fluticasone furoate: 2 sprays ( mcg/spray) in each nostril once a day
Fluticasone propionate: 1 or 2 sprays (50 mcg/spray) in each nostril once a day as needed
-Children between 2 to 11 years not adequately responding to 55 mcg may use 110 mcg (2 sprays in each nostril) once a day.
-When maximum benefit has been achieved and symptoms have been controlled, reducing the dosage to 55 mcg (1 spray in each nostril) once a day may be effective.
Use: Treatment of symptoms of seasonal and perennial allergic rhinitis
Drinking alcohol may cause rhinitis as well as worsen asthma (see alcohol-induced respiratory reactions ). In certain populations, particularly those of East Asian countries such as Japan, these reactions have a nonallergic basis.  In other populations, particularly those of European descent, a genetic variant in the gene that metabolizes ethanol to acetaldehyde, ADH1B, is associated with alcohol-induced rhinitis. It is suggested that this variant metabolizes ethanol to acetaldehyde too quickly for further processing by ALDH2 and thereby leads to the accumulation of acetaldehyde and rhinitis symptoms.   In these cases, alcohol-induced rhinitis may be of the mixed rhinitis type and, it seems likely, most cases of alcohol-induced rhinitis in non-Asian populations reflect true allergic response to the non-ethanol and/or contaminants in alcoholic beverages, particularly when these beverages are wines or beers.  Alcohol-exacerbated rhinitis is more frequent in individuals with a history of rhinitis exacerbated by aspirin. 
The precise mechanism through which fluticasone propionate affects rhinitis symptoms is not known. Corticosteroids have been shown to have a wide range of effects on multiple cell types (., mast cells, eosinophils, neutrophils, macrophages, lymphocytes) and mediators (., histamine, eicosanoids, leukotrienes, cytokines) involved in inflammation. In 7 trials in adults, fluticasone propionate nasal spray has decreased nasal mucosal eosinophils in 66% of patients (35% for placebo) and basophils in 39% of patients (28% for placebo). The direct relationship of these findings to long-term symptom relief is not known.